# A Study of Herceptin (Trastuzumab) Combination Therapy in Patients With Metastatic Urothelial Cancer

> **NCT02006667** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 13 (actual)

## Conditions studied

- Urinary Tract Cancer

## Interventions

- **DRUG:** trastuzumab
- **DRUG:** gemcitabine
- **DRUG:** cisplatin

## Key facts

- **NCT ID:** NCT02006667
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-01
- **Primary completion:** 2010-01
- **Final completion:** 2010-01
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2015-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02006667

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02006667, "A Study of Herceptin (Trastuzumab) Combination Therapy in Patients With Metastatic Urothelial Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02006667. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*